What question did this study set out to answer?

To evaluate the efficacy of dual targeting of EZH2 and dopamine D1 receptor for suppressing TNBC growth and metastasis.

Dual Targeting of EZH2 and Dopamine D1 Receptor Suppresses TNBC Growth and Metastasis

View Full Paper

Ask AI

Bookmark

Authors

Combination therapy shows a reduction in tumor growth and metastasis in triple-negative breast cancer, suggesting new treatment avenues.

To evaluate the efficacy of dual targeting of EZH2 and dopamine D1 receptor for suppressing TNBC growth and metastasis.
Utilized computational modeling with AlphaFold EZH2 structure and various ligands.
Conducted docking studies to assess binding interactions of GSK126 with EZH2.
Performed immunoprecipitation assays to validate EZH2-D1R interactions.
Administered combination therapy in 2D cell cultures and tumor spheroid models.
Tested treatment effects in a vascularized organ-on-chip model.
Combination therapy showed a combination index of 0.24, indicating strong synergy in reducing 2D cell viability.
In tumor spheroids, the combination reduced size by 62% and caused necrosis.
EZH2 degradation and cytoskeletal disruption were observed via confocal imaging.
In an organ-on-chip model, circulating tumor cells were reduced by 50%.

Drago et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark